REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
12/15/2025
Back to search
Official data from USPTO
IDERA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
17
Latest update
12/16/2025
Trademark type
Combined
Nice classes
5
Filing date
09/25/2019
Registration date
12/15/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/15/2020
Last transaction
12/16/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2008-06-00
First use in commerce
2008-06-00
Drawing code
3
Owner type
03
Owner location
Cambridge, MA
Examiner
DUBRAY,KATHERINE M
Law office
M90
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the word "IDERA" and a design element. The design element is positioned above and to the left of the word "IDERA" and consists of six circles around a common center. Four of those circles are connected to matching circles such that they resemble cells that are in the act of splitting. One of the two other circles forms the dot in the letter "I" in "IDERA".
Holders and representatives
Holders
Idera Pharmaceuticals, Inc.
Representatives
Rebecca E. McDougall MORGAN, LEWIS & BOCKIUS LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medical therapeutic preparationsbiologically active modulatorsbiologically active immune modulatorsbiologically active antisense DNA or RNA compoundschemical modulators of gene expression working at DNA transcriptionRNA or translation processes; immunomodulatory oligonucleotidesingredients that enhance or induce an immune response as a component part in a pharmaceutical preparation; pharmaceutical and vaccine adjuvants to enhance the immune system response; pharmaceuticals for use in the treatment of viral and bacterial infectioninflammatory disorders and diseasescancerauto immune diseases and disorders and vaccine adjuvants to modulate the immune system; biologically active pharmaceutical compounds for use in the treatment of viral and bacterial infection or diseases associated with cellular gene expressions by preventing the production of disease associated proteins made by said infectious agents or cellular genes
Publications
History of USPTO decisions and trademark events.
17 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/15/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
11/07/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
11/06/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/15/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/15/2020
IUAF
USE AMENDMENT FILED
09/29/2020
EISU
TEAS STATEMENT OF USE RECEIVED
09/29/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
03/31/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/04/2020
PUBO
PUBLISHED FOR OPPOSITION
02/04/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/15/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/27/2019
DOCK
ASSIGNED TO EXAMINER
12/27/2019
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/02/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/01/2019
NWAP
NEW APPLICATION ENTERED
09/28/2019
Continuous trademark protection
Get notified about every new filing that threatens IDERA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.